NCAM1 and neoplasm: Preliminary experiments showed that supernatants from tumours treated with any of the drugs had no direct effect on the numbers and/or activation states of NKs (CD3−, CD69+, CD56+ and CD16+), T cells (CD3+, CD25+ and CD69+) and T-regs (CD4+, CD25+ and Foxp3+).